ALBIREO PHARMA INC's ticker is ALBO and the CUSIP is 01345P106. A total of 105 filers reported holding ALBIREO PHARMA INC in Q2 2022. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $334,004 | +12.1% | 15,456 | +0.5% | 0.00% | 0.0% |
Q3 2022 | $298,000 | -60.3% | 15,381 | -59.3% | 0.00% | -66.7% |
Q2 2022 | $751,000 | -54.9% | 37,836 | -32.3% | 0.00% | -50.0% |
Q1 2022 | $1,667,000 | -1.7% | 55,871 | -23.3% | 0.01% | +20.0% |
Q4 2021 | $1,696,000 | -35.0% | 72,838 | -12.9% | 0.01% | -44.4% |
Q3 2021 | $2,609,000 | +22.5% | 83,613 | +38.1% | 0.01% | +28.6% |
Q2 2021 | $2,130,000 | +1.7% | 60,542 | +1.9% | 0.01% | -12.5% |
Q1 2021 | $2,095,000 | +3.7% | 59,425 | +10.3% | 0.01% | +14.3% |
Q4 2020 | $2,021,000 | +26.6% | 53,873 | +12.7% | 0.01% | 0.0% |
Q3 2020 | $1,596,000 | +63.5% | 47,814 | +29.8% | 0.01% | +40.0% |
Q2 2020 | $976,000 | +47.4% | 36,844 | -8.9% | 0.01% | +25.0% |
Q1 2020 | $662,000 | -33.4% | 40,426 | +3.4% | 0.00% | -20.0% |
Q4 2019 | $994,000 | +6.0% | 39,088 | -16.7% | 0.01% | 0.0% |
Q3 2019 | $938,000 | -39.5% | 46,915 | -2.5% | 0.01% | -44.4% |
Q2 2019 | $1,551,000 | +65.0% | 48,110 | +64.8% | 0.01% | +50.0% |
Q1 2019 | $940,000 | +39.3% | 29,199 | +6.1% | 0.01% | +20.0% |
Q4 2018 | $675,000 | – | 27,522 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Prosight Management, LP | 270,146 | $6,627,000 | 3.42% |
Perceptive Advisors | 1,704,330 | $39,506,000 | 1.50% |
Birchview Capital, LP | 38,000 | $932,000 | 0.88% |
SECTORAL ASSET MANAGEMENT INC | 229,978 | $5,641,000 | 0.77% |
BVF INC/IL | 200,500 | $4,918,000 | 0.64% |
Artal Group S.A. | 500,000 | $12,265,000 | 0.45% |
PA Capital LLC | 14,692 | $360,000 | 0.38% |
Chicago Capital, LLC | 180,911 | $4,438,000 | 0.36% |
TPG Group Holdings (SBS) Advisors, Inc. | 716,381 | $17,573,000 | 0.28% |
Fosun International Ltd | 197,005 | $4,492,000 | 0.27% |